Background: Oral fluid is currently being evaluated as an alternative matrix for monitoring illicit drugs in federally mandated workplace drug testing, for addiction treatment programs, and for driving under the influence testing. The sensitivity, specificity, and efficiency of the Cozart ® Microplate EIA Cocaine Oral Fluid Kit (COC ELISA) were determined by comparison with gas chromatography-mass spectrometry (GC/MS) results at screening and confirmation cutoffs proposed in the US and UK. Method: Oral fluid was collected by expectoration after citric acid candy stimulation or with Salivette ® neutral cotton swabs or Salivette citric acid-treated cotton swabs before and after cocaine (COC) administration. Specimens (n ‫؍‬ 1468) were analyzed with the COC ELISA for screening and with solid-phase extraction followed by GC/MS for confirmation. Three screening cutoffs (10, 20, and 30 g/L) and four GC/MS cutoffs (2.5, 8, 10, and 15 g/L COC, benzoylecgonine, and/or ecgonine methyl ester) were evaluated. GC/MS limit of quantification was 2.5 g/L for all analytes. Results: COC ELISA interassay imprecision (CV; n ‫؍‬ 19) was 16% at 16.7 g/L and 12% at 81.8 g/L. With the 2.5, 8, 10, and 15 g/L GC/MS cutoffs, 59.0%, 54.7%, 52.7%, and 48.7% of the oral fluid specimens were positive, respectively. Sensitivity, specificity, and efficiency were 92.2%, 84.7%, and 88.8%, respectively, for the suggested Substance Abuse and Mental Health
fluid screening cutoff of 20 g/L with BE as the target analyte and confirmation cutoffs of 8 g/L COC and/or BE. In the UK, a screening cutoff of 30 g/L and a confirmation cutoff of 15 g/L for COC, BE, and/or EME in oral fluid have been used. Additional cutoffs, including a cutoff at the limits of quantification (LOQ) of the screening (10 g/L) and confirmation assays (2.5 g/L), and a 10 g/L screen, and a 10 g/L confirmation cutoff, were evaluated.
The purpose of this study was to evaluate the sensitivity, specificity, and efficiency of the Cozart ® Microplate EIA Cocaine Oral Fluid Kit (COC ELISA) as a routine screening method for detecting COC use and to evaluate proposed cutoffs for immunoassay and gas chromatography-mass spectrometry (GC/MS) analysis of COC and its metabolites in oral fluid.
Materials and Methods human participants
Eleven male and 7 female healthy volunteers participated in a controlled drug administration protocol. Of the 18 participants, 14 were African American, 2 were Caucasian, and 2 were Hispanic. Their mean (SD) age was 35.3 (4.5) years (range, 23-43 years), and their mean weight was 75.7 (12.5) kg (range, 56.6 -96.2 kg). The protocol was approved by the National Institute on Drug Abuse Institutional Review Board. Participants provided written informed consent and were paid for their participation. Screening procedures included comprehensive physical and psychologic examinations. Participants reported a history of COC and opioid use, verified by a positive urine test before admission, and were not physically dependent on drugs or medications, with the possible exception of nicotine and caffeine. During the 10-week study, all participants resided on the closed research unit of the Intramural Research Program, National Institute on Drug Abuse.
drug administration
COC hydrochloride for human administration was obtained from Mallinkrodt and was prepared in saline for subcutaneous injection. Participants received three low doses (75 mg/70 kg) of COC hydrochloride within 7 days and, after a 3-week interval, three high doses (150 mg/70 kg) within 7 days.
specimens
Oral fluid was collected before and up to 72 h after COC administration by citric acid candy stimulation and expectoration (n ϭ 1100). Smaller subsets were collected with Salivette ® neutral cotton swabs (n ϭ 165) or Salivette citric acid-treated cotton swabs (n ϭ 203). A mean (SD) of 82 (45) oral fluid specimens were collected (range, 26 -169) per participant. The Salivette neutral and citric acidtreated cotton swabs were placed between the cheek and gum or under the individual's tongue until saturated with oral fluid. The cotton swab was sometimes chewed to stimulate oral fluid production. Saturation could occur in 30 -45 s but always was completed within 3-4 min. After collection, the swab was centrifuged to release ϳ1-1.5 mL of clear oral fluid. Oral fluid collection was supervised by trained research associates and medical staff. Subsequently, oral fluid was transferred to polypropylene cryotubes and frozen at Ϫ20°C until analysis. A total of 602 negative specimens were included in the study. The limit of detection of the GC/MS method (2.5 g/L) was used to differentiate positive and negative specimens. Specimens with COC, BE, EME, and cocaethylene (CE) Ͻ2.5 g/L were considered negative.
cozart microplate eia cocaine oral fluid
The COC ELISA is a competitive enzyme immunoassay for the detection of COC in human oral fluid, developed by Cozart Bioscience Ltd. The assay was performed according to manufacturer's directions. Briefly, 25 L of oral fluid specimen, calibrator, or quality-control sample was added to a microtiter plate well coated with anti-BE antibody, and 100 L of enzyme conjugate was added. Each microtiter plate was calibrated in duplicate with 0, 10, 25, 50, and 100 g/L BE calibrators. Duplicate qualitycontrol samples were interspersed within each plate. Participant oral fluid samples were assayed in singlate. After a 30-min incubation, the plate was washed, and 100 L of substrate solution (3,3Ј,5,5Ј-tetramethylbenzidine) was added, followed by another 30-min incubation. Finally, 100 L of stop solution (1 mol/L sulfuric acid) was added, and the absorbance at 450 nm measured within 30 min with a microplate reader (Dynex Technologies).
For the pilot study of pH effect on COC ELISA, oral fluid was collected from healthy volunteers with Salivette citric acid-treated cotton swabs (n ϭ 12) and verified to be drug free, and the pH was determined. Oral fluid specimens were assayed with the COC ELISA, and absorbance was recorded at 450 nm as described above. 
chemicals and reagents

gc/ms procedure
Calibrators, quality-control samples, and oral fluid samples were analyzed for COC and its metabolites by solid-phase extraction according to a previously published procedure (15) (16) (17) (18) . COC, BE, EME, and CE calibraClinical Chemistry 49, No. 9, 2003 tors were prepared at drug concentrations of 1.25-1000 g/L in drug-free oral fluid. Different stock solutions of COC, BE, EME, and CE at 0, 10, 100, and 500 g/L were added to drug-free oral fluid to prepare quality-control samples. Specimens were analyzed with a low (2.5-50 g/L) or high calibration curve (50 -500 g/L). Split curves were required to obtain suitable sensitivity and linearity (r Ն0.98) for the four analytes.
GC/MS analysis was performed on a Hewlett-Packard 5890A or 5973 gas chromatograph interfaced with a Hewlett-Packard 5972 or 6890 mass-selective detector in splitless mode. Chromatographic conditions have been published previously (16 Ion ratios of quality-control samples and participant samples were required to be within Ϯ 20% of those observed for the 10 and 100 g/L calibrators for the low and high calibration curves, respectively. The limit of detection and the LOQ of the method were 2.5 g/L for all analytes.
imprecision (cv), sensitivity, specificity, and efficiency
Interassay precision for the low and high quality-control specimens was calculated from 35 and 37 sample results, respectively, assayed in 19 batches. Duplicate qualitycontrol samples were included in each full batch.
The numbers of true-positive (TP), false-negative (FN), false-positive (FP), and true-negative (TN) specimens were determined by comparison of immunoassay with GC/MS results. For the purposes of this comparison, three different screening test cutoffs (10, 20 , and 30 g/L) and four GC/MS cutoffs (2.5, 8, 10, and 15 g/L COC, BE, and/or EME) were evaluated. Screening cutoffs were selected because the lowest calibrator for the COC ELISA screen is 10 g/L, the proposed SAMHSA cutoff is 20 g/L, and the cutoff used in the UK is 30 g/L. Confirmation cutoffs were chosen because 2.5 g/L is the LOQ of the GC/MS method, the proposed SAMHSA cutoff is 8 g/L, Niedbala et al. (19 ) evaluated 10 g/L with a different ELISA for COC in oral fluid, and the UK cutoff is 15 g/L. A sample was considered TP if both the immunoassay and GC/MS were positive for COC, BE, and/or EME and TN if both results were negative. A sample was considered FP if the immunoassay result was positive and the GC/MS result was negative for COC, BE, and/or EME. A sample was considered FN if the immunoassay result was negative and the GC/MS result was equal to or above the specified cutoff for any of the three analytes. Sensitivity was calculated as TP/(TP ϩ FN) ϫ 100 and specificity as TN/(TN ϩ FP) ϫ 100. Efficiency was calculated as (TP ϩ TN)/total number of specimens ϫ 100.
Results and Discussion
Interest in the use of alternative matrices for drug testing has led to development of many new assays. Immunoassays for drugs of abuse can be used to screen serum, whole blood, oral fluid, sweat, and hair as well as urine (1-3, 19 -21 ) . Advantages of these screening tests include their simplicity, rapidity, sensitivity, and reduced cost. The COC ELISA was developed for the qualitative and semiquantitative determination of COC and metabolites in oral fluid.
Interassay imprecision (CV) of the COC immunoassay (based on g/L of the quality-control specimens) was 16% at a mean concentration of 16.7 g/L (n ϭ 19) and 12% at a mean concentration of 81.8 g/L (n ϭ 19).
Oral fluid specimens (n ϭ 1468) included 602 negative samples (41.0%) and 866 positive specimens (59.0%) for COC, BE, and/or EME with a 2.5 g/L GC/MS cutoff. There were 519 (35.4%) oral fluid specimens positive for COC, 799 (55.2%) positive for BE, and 696 (47.4%) positive for EME. Concentrations in oral fluid ranged from 2.5 to 8845.0 g/L for COC, 2.5 to 757.0 g/L for BE, and 2.5 to 1024.3 g/L for EME. The percentages of oral fluid specimens positive for COC and its metabolites at the different screening cutoffs were 71.6% (10 g/L cutoff), 57.0% (20 g/L cutoff), and 49.0% (30 g/L cutoff) and at the different confirmation cutoffs were 59.0% (2.5 g/L cutoff), 54.7% (8 g/L cutoff), 52.7% (10 g/L cutoff), and 48.7% (15 g/L cutoff) for COC, BE, and/or EME. Although recovery studies were not performed as part of this study, recovery of basic drugs, including COC, from c Cutoffs currently used in the UK for COC and metabolites in oral fluid: 30 g/L screening cutoff and 15 g/L confirmation cutoff for COC, BE, and/or EME.
d TP, FP, TN, and FN were determined for the specified cutoffs by comparison of the immunoassay result with the GC/MS result (see text). e Sensitivity, specificity, and efficiency were calculated using the following formulas:
the Salivette cotton roll were estimated to be at least 80 -90% based on results published by Samyn et al. (22 ) . TN, FP, FN, and TP results at specified screening and confirmation cutoffs are shown in Table 1 . All evaluated cutoffs had sensitivities Ն89% and efficiencies Ն80%. With the proposed SAMHSA criteria, which required GC/MS analysis of only COC and BE, we found a sensitivity of 92.2%, a specificity of 84.7%, and an efficiency of 88.8%. Adding EME to the GC/MS confirmation identified only 3 additional TP results (from 734 to 737) with little change in test efficiency (from 88.8% to 88.7%). The use of the proposed SAMHSA cutoffs gave improved results for specificity and efficiency, increases of 18.8% and 4.1%, respectively, with a decrease in sensitivity of Ͻ5.5% compared with the lowest (10/2.5 g/L) cutoffs. The sensitivity, specificity, and efficiency of the UK cutoff were similar to those of the SAMHSA cutoffs, with the highest efficiency among the evaluated cutoffs. However, there were 92 fewer TP samples (642) compared with SAMHSA. The highest sensitivity (99.0%) and lowest specificity (58.8%) were obtained at the 10/10 g/L cutoffs, which considered a sample as positive with COC, BE and/or EME Ն 10 g/L. Niedbala et al. (19 ) reported sensitivity (95%), specificity (82%), and efficiency (88%) data for the STC Cocaine Metabolites MICRO-PLATE EIA with a 10 g/L screening cutoff and a 10 g/L combined cutoff concentration for COC and BE by GC/MS. The LOQ for COC and BE were 4.0 and 7.0 g/L, respectively. Sensitivity results were comparable to those reported in our study, but there was a major difference in specificity because of the larger number of FP results in our data. This was most likely attributable to differences in GC/MS cutoffs and to possible differences in the cross-reactivities of the respective antibodies.
As observed for the total specimen set of 1468 oral fluid specimens (Table 1) , the number of FP specimens varies depending on the screening and confirmation cutoffs used (14% for the 10/2.5 g/L cutoffs, 19% for the 10/10 g/L cutoffs, 6.8% for the 20/8 g/L cutoffs, 7.0% for the SAMHSA cutoff, and 5.3% for the UK cutoffs). In addition, the percentage of FP specimens also varies with the type of oral fluid collection device, as seen in Table 2 . a Cozart COC ELISA screening cutoff for COC, BE, and/or EME: confirmation cutoff by GC/MS. b Proposed SAMHSA cutoffs for COC and metabolites in oral fluid: 20 g/L screening cutoff and 8 g/L confirmation cutoff for COC and/or BE. c Cutoffs currently used in the UK for COC and metabolites in oral fluid: 30 g/L screening cutoff and 15 g/L confirmation cutoff for COC, BE, and/or EME. d TP, FP, TN, and FN were determined for the specified cutoffs by comparison of the immunoassay result with the GC/MS result (see text). e Sensitivity, specificity, and efficiency were calculated using the following formulas:
Therefore, when evaluating the FP results produced by an immunoassay, these factors need to be taken into consideration. Comparison of percentages of FP results of different immunoassays with the same cutoffs and the same collection system would be the best means of determining differences attributable to antibody cross-reactivity. We have shown that the low pH produced in specimens collected with the Salivette with citric acid-treated cotton swab yielded a higher percentage of FP results compared with specimens collected after citric acid candy expectoration (20.2% vs 4.1% at the SAMHSA cutoff). The primary purpose of the screening assay is to identify potential positive specimens (high sensitivity is needed), and the primary purpose of the confirmation test is to eliminate negative specimens (high specificity is needed). Although GC/MS confirmation of FP specimens is timeconsuming and costly, lowering the number of presumptive positive specimens in the immunoassay usually increases the number of FN specimens. FN specimens tend to undermine the deterrent effect of drug testing in workplace and treatment programs and could have public health consequences if individuals driving under the influence of drugs fail to be identified. Our results, obtained after controlled COC administration and analysis of oral fluid specimens by immunoassay and GC/MS, provide objective data to evaluate these factors and to select screening and confirmation cutoffs to meet the goals of the individual drug testing programs. Cross-reactivities of the antibodies in the ELISA screen were reported to be 72% for COC, 100% for BE, Ͻ0.1% for EME, and 221% for CE (23 ) . The low cross-reactivity to EME supports the finding that the addition of EME to the proposed SAMHSA cutoffs had a minimal effect on the sensitivity and efficiency of this COC ELISA. EME is a major COC metabolite in oral fluid along with BE; however, almost all EME-positive specimens were also positive for COC and/or BE. CE may be found in body fluids of individuals who concurrently use COC and ethanol (24 -28 ) . CE concentrations in seven human postmortem blood samples ranged from 73 to 1447 g/L, with four of the seven samples having higher CE than COC concentrations (25 ) . Bailey (28 ) The high cross-reactivity of CE with the COC ELISA suggested that some of the FP immunoassay results could be attributable to the presence of CE. We found CE concentrations of 2.5-104.4 g/L, always with high concentrations of COC, BE, and/or EME. The mean ratios of CE to COC, BE, and EME in oral fluid were 0.020 (SD, 0.029; range, 0.002-0.214), 0.358 (SD, 0.422; range, 0.014 -1.931), and 0.332 (SD, 0.444; range, 0.018 -2.612), respectively. There were no cases where CE was present without concurrent COC, BE, and/or EME concentrations greater than the cutoff. Therefore, the presence of CE did not produce FP results and did not lower the specificity of the COC ELISA.
Comparisons of the sensitivities, specificities, and efficiencies for the different oral fluid collection methods are shown in Table 2 . In specimens collected with citric acid candy expectoration (n ϭ 1100) and with the Salivette with neutral cotton swab (n ϭ 165), the sensitivities, specificities, and efficiencies were similar. In the oral fluid specimens obtained with the Salivette with citric acidtreated cotton swabs (n ϭ 203), sensitivity (Ͼ95%) compared closely with that of the other collection methods, but specificity was low at all cutoffs because of the high number of FP samples. Specimens obtained with all three methods were assayed together on the same ELISA plates. Furthermore, quality-control samples included on the plates produced accurate semiquantitative results, leading to the conclusion that analytical errors were not the source of these discrepancies. We reported earlier that the mean (SD) pH of oral fluid specimens collected with the Salivette with citric acid-treated cotton swabs [pH 2.8 (0.3)] was lower than that observed after citric acid candy expectoration [pH 4.3 (0.8)] (18 ). The latter was also 1.7 pH units lower than that of the mean pH of specimens collected with the Salivette with neutral cotton swabs [pH 6.0 (0.6)]. Niedbala et al. (19 ) reported that there was no significant effect of oral fluid pH on the STC Cocaine Metabolite MICRO-PLATE EIA when the sample pH was between 5.0 and 9.0. Schwartz et al. (29 ) reported that lemon-lime-flavored Crystal Light ® powdered drink mix crystals lowered oral fluid pH and increased cortisol concentrations by RIA. The lower the pH (Յ4), the more the cortisol concentration was increased. In our pilot study of pH effects on the COC ELISA, we found a correlation between oral fluid pH and absorbance (Fig. 1) . There was substantial intersubject variability in pH (range, 2.79 -7.18) in drug-free oral fluid specimens collected with the Salivette with citric acid cotton swabs (n ϭ 12). Oral fluid samples with pH Ͻ4 had absorbances close to the COC ELISA cutoff of 10 g/L or lower and, therefore, sometimes yielded FP results. The low pH in oral fluid samples collected with the Salivette with citric acid cotton swabs is most likely the source of the FP results observed in this group of samples. It appears that low salivary pH interferes with enzyme-labeled BE binding to anti-BE antibody to produce FP results with the COC ELISA. These data provide important information about the effect of pH on oral fluid immunoassays and suggest caution in selection of an oral fluid collection method.
In conclusion, based on the results of the present study, COC, BE, and EME are appropriate oral fluid analytes for screening and confirming COC use. This controlled COC administration study demonstrates that the Cozart Microplate EIA Cocaine Oral Fluid Kit provides a suitable screening procedure for the identification of COC exposure. The proposed SAMHSA and UK cutoffs provided similar sensitivity, specificity, and efficiency, but with the SAMHSA cutoffs, 92 additional TP samples were identified.
